CD19 and lymphoma: To evaluate the tumor-targeting efficacy and mechanism of action (MOA) of CAR-iNKT cells, we employed three tumor cell lines: the CD19+ human lymphoma line Raji, the CD19- human melanoma line A375, and an engineered A375 line overexpressing CD19 (A375-CD19).